$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
帕博西林乳腺癌治疗新选择
2025-10-19 11:44:20
Check Details
mTOR拟制剂依维莫司带来治疗激素受体阳性晚期乳腺癌的新突破
2025-10-19 11:44:20
Check Details
内分泌治疗联合依维莫司可治疗芳香化酶失败后的晚期乳腺癌
2025-10-19 11:44:20
Check Details
尼拉帕尼治疗存在BRCA突变的乳腺癌
2025-10-19 11:44:20
Check Details
帕博西林联合来曲唑治疗晚期乳腺癌
2025-10-19 11:44:20
Check Details
依维莫司联合依西美坦治疗乳腺癌
2025-10-19 11:44:20
Check Details
帕博西尼联合来曲唑治疗HER 2-乳腺癌患者
2025-10-19 11:44:20
Check Details
帕博西尼+来曲唑延长乳腺癌患者的无进展生存期
2025-10-19 11:44:20
Check Details
帕博西尼治疗乳腺癌优于来曲唑
2025-10-19 11:44:20
Check Details
转移性乳腺癌的一线用药帕博西林联合芳香化酶抑制剂
2025-10-19 11:44:20
Check Details
依维莫司的注意事项
2025-10-19 11:44:20
Check Details
尼拉帕尼为乳腺癌患者提供了新的治疗选择
2025-10-19 11:44:20
Check Details
1
2
...
1649
1650
1651
1652
1653
1654
1655
...
4150
4151
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Alectinib for ALK-Positive Lung Cancer: Efficacy, Side Effects & Clinical Outlook
2
Which Generation TKI Is Repotrectinib? Professional Analysis of Next-Gen ROS1 Inhibitor Classification and Clinical Features
3
Dietary Guide During Goserelin Treatment: Scientific Nutrition Management to Alleviate Side Effects and Improve Quality of Life.
4
CYP26A1 Gene Emerges as New Target for Colorectal Cancer Treatment! Folate Metabolism Research Brings Hope for Immunotherapy.
5
Precision Breakthrough: Inavolisib Redefines Survival in PIK3CA-Mutant Breast Cancer
6
Optimal Regorafenib (Stivarga) Administration Guide: Low-Fat Diet, Fixed Timing, and Dose Escalation Strategies
7
Guidelines for the timing, method, and precautions of taking Erlotinib (Trokai).
8
Important Information for Safe Use of Ibrutinib
9
Comprehensive description of palbociclib
10
Pralsetinib: The RET Precision-Targeted Therapy That Rewrites the Treatment History of Rare Cancers
11
Detailed introduction to the instruction manual of revumenib
12
Ryeqo (Relugolix compound tablets) - long-term treatment for uterine fibroids